Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$92.62 USD

92.62
778,003

-0.46 (-0.49%)

Updated Apr 18, 2024 03:49 PM ET

After-Market: $92.58 -0.04 (-0.04%) 4:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for NVS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Novartis AG falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 14,428 18,930 28,329 11,563 11,446
Receivables 7,533 8,334 8,283 8,456 8,555
Notes Receivable 0 0 0 0 0
Inventories 5,913 7,175 6,666 7,131 5,982
Other Current Assets 2,607 2,471 2,440 2,523 3,521
Total Current Assets 30,481 36,910 45,718 29,673 29,504
Net Property & Equipment 9,514 10,764 11,545 12,263 12,069
Investments & Advances 2,812 2,554 3,241 9,632 11,162
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 4,309 3,739 3,743 8,214 7,909
Intangibles 50,220 60,945 63,777 66,808 55,311
Deposits & Other Assets 1,199 1,110 2,210 3,793 738
Total Assets 99,945 117,453 131,795 132,059 118,370
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 4,926 5,146 5,553 5,403 5,424
Current Portion Long-Term Debt 6,175 5,931 6,295 9,785 7,031
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 1,893 2,533 2,415 2,458 2,194
Other Current Liabilities 13,166 14,795 15,670 15,127 13,369
Total Current Liabilities 26,390 28,656 30,208 33,059 28,264
Mortgages 0 0 0 0 0
Deferred Taxes/Income 2,248 2,686 3,070 7,422 5,867
Convertible Debt 0 0 0 0 0
Long-Term Debt 18,436 20,244 22,902 26,259 20,353
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 4,523 4,906 6,172 6,934 6,632
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 53,195 58,030 63,973 75,393 62,819
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 825 890 901 913 936
Capital Surplus 0 0 0 0 0
Retained Earnings 45,883 58,544 66,802 55,738 54,618
Other Equity 83 81 167 68 77
Treasury Stock 41 92 48 53 80
Total Shareholder's Equity 46,750 59,423 67,822 56,666 55,551
Total Liabilities & Shareholder's Equity 99,945 117,453 131,795 132,059 118,370
Total Common Equity 46,750 59,423 67,822 56,666 55,551
Shares Outstanding 2,119.60 2,119.60 2,236.70 2,288.70 2,265.00
Book Value Per Share 22.06 28.04 30.32 24.76 24.53

Fiscal Year End for Novartis AG falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 14,428 12,695 11,174 12,260
Receivables NA 7,533 7,099 9,543 9,183
Notes Receivable NA 0 0 0 0
Inventories NA 5,913 5,610 8,228 7,886
Other Current Assets NA 2,607 20,256 4,548 2,785
Total Current Assets NA 30,481 45,660 33,493 32,114
Net Property & Equipment NA 9,514 9,044 10,825 10,841
Investments & Advances NA 2,812 2,122 2,433 2,555
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 4,309 3,628 4,043 4,081
Intangibles NA 50,220 49,834 57,525 59,932
Deposits & Other Assets NA 1,199 1,109 1,208 1,211
Total Assets NA 99,945 112,697 110,979 112,241
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 4,926 3,870 5,350 5,426
Current Portion Long-Term Debt NA 6,175 5,458 8,289 6,968
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 1,893 2,129 2,651 2,966
Other Current Liabilities NA 13,166 36,726 15,372 14,938
Total Current Liabilities NA 26,390 48,393 31,909 30,549
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 2,248 2,457 2,526 2,727
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 18,436 18,068 18,259 20,396
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 4,081 4,809 4,838
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 53,195 74,452 59,048 60,099
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 825 825 842 842
Capital Surplus NA 0 0 0 0
Retained Earnings NA 45,883 37,371 51,057 51,253
Other Equity NA 83 81 84 83
Treasury Stock NA 41 32 52 36
Total Shareholder's Equity NA 46,750 38,245 51,931 52,142
Total Liabilities & Shareholder's Equity NA 99,945 112,697 110,979 112,241
Total Common Equity 0 46,750 38,245 51,931 52,142
Shares Outstanding 2,119.60 2,119.60 2,119.60 2,119.60 2,119.60
Book Value Per Share 0.00 22.06 18.04 24.50 24.60